Poster Session: Clinical Trials – Methodology
Title: Alzheimer’s Disease Pivotal Trial Design for Zervimesine Following an End of Phase 2 Meeting with FDA
Authors: Jennifer F. Iaci, MS, Michael Grundman, MD, MPH, Nigel A.S. Hernandez, PhD, MSc, RAC, and Anthony O. Caggiano, MD, PhD
For more information, please visit: https://www.ctad-alzheimer.com/
Cognition Therapeutics
info@cogrx.com
Mikey Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
